COVID-19, Moderna Therapeutics mRNA Vaccine, and Crichton
I understood how some combinations of drugs work in attacking Covid-19 with one drug acting as an ionophore allowing another drug to enter a cell and attach to Covid RNA stopping its replication. I found this nice chart on National Geographic offering up an educational semi -medical and microbiologist depiction of how Moderna’s new vaccine mRNA gives the human body the ability to attack Covid. I duplicated the chart with the original wording on Power Point. Click on either chart to make them larger.
Where we are today, Some history, and Where this is going
Moderna’s mRNA has moved into a Phase III Clinical Trial stage testing in the treatment of Covid-19. It is considered to be more successful than the other drugs and it is being fast-tracked (Operation Warp-Speed [or “Tribble Infestation”]) by the administration. On May 18 of this year, Moderna Therapeutics announced preliminary findings that healthy subjects had responded to mRNA vaccine by producing “neutralizing antibodies” which is how the vaccine works in the treatment of Covid. The antibodies made by the immune system prevent infection by the coronavirus.
When a virus infects a body, the immune system scrambles to recognize and create a response. The more traditional results of vaccine development is the introduction of an inactivated or weakened form of a virus or introduce one of the virus’s viral proteins to the body. The immune system responds to the introduction by producing antibodies to counter the vaccine, recognizing particular proteins of the virus. Those antibodies can fight future infections as long as the virus does not evolve.
The mRNA vaccine takes a novel or a new and different approach of introducing Messenger RNA of which RNA has never been approved or licensed for human use. One of the pluses of the usage of mRNA vaccine is it can be manufactured faster as it bypasses the traditional methods of producing inactivated viruses or isolating proteins. Messenger RNA ([which mRNA is] a single-stranded RNA molecule that is complementary to one of the DNA strands of a gene) is genetic material made of nucleic acid— the same stuff as our DNA — that travels throughout our cells, giving final instructions on which proteins to build to form the body’s cellular architecture.
Put another way:
Plasmid DNA and now mRNA vaccines have generated significant interest and efforts because of their potential as platform technologies that could be used for a variety of applications ranging from prophylaxis to therapy and from personalized medicine to global health solutions. Both can be quickly made with fairly generic manufacturing processes and can be constructed directly from the genetic sequence of the desired protein, whether the origin of the protein is human or from a pathogen. For vaccines, making a gene construct coding for the antigen instead of inactivating or attenuating the pathogen, or instead of making a recombinant protein, is vastly easier, more rapid, and avoids potential risks of working with live pathogens. Likewise, the vaccine construct can encode only the key antigen without including other proteins that may be either deleterious (such as toxins) or that may be irrelevant for protection yet immunodominant.
I can’t put my finger on which book it was (“The Prey?” – there are others). This reads almost like a Michael Crichton story where man tampers with DNA and causes harm to himself. “In the early 1990s, scientists wondered what would happen if they manufactured pieces of viral DNA (and mRNA) and then injected them into human cells or lab animals. The hope was that the cells would take in the genetic snippets, make viral proteins, and trigger an immune response.”
Moderna Therapeutics came to rely on a popular tool for drug delivery called lipid nanoparticles (similar talked about in “Prey”). By packing genetic material inside a slippery pod made of oily lipids, these particles could easily slide mRNA into cells, where it could go to work. With safer mRNA technology and better drug delivery, the company was able to expand its portfolio and pursue remedies for cancer and a range of infectious diseases , including the flu.
From what I am reading in various sources, mRNA appears to be programing cells to recognize the virus by using the genetic sequence of the desired protein, whether the origin of the protein is human or from a pathogen, injecting it into the cells utilizing a lipid coating, and using it to instruct the Ribosome within cells to produce antigens impacting cells to create the antibodies. The cell is programmed by injecting genetic material into a deltoid, etc. muscle, giving cells a blueprint for making the spike protein receiving mRNA used to initiate the creation of antibodies (see chart) before being exposed to Covid.
This is new, terribly interesting, and fraught with potentially dangerous reactions as we scurry along under this administration’s demands.
Some References:
“COVID-19 and mRNA Vaccines—First Large Test for a New Approach.” JAMA Network, Jennifer Abbasi September 3, 2020
“Moderna’s mRNA vaccine reaches its final phase. Here’s how it works,” National Geographic, Nsikan Sikan Akpan, July 27, 2020
“Dozens of COVID-19 vaccines are in development. Here are the ones to follow.”, National Geographic, Amy McKeever, September 14, 2020
“A Comparison of Plasmid DNA and mRNA as Vaccine Technologies“,MDPI, Margaret A. Liu, April 19, 2019
DIANA MARQUES, NGM STAFF. KELSEY NOWAKOWSKI
SOURCE: HMS COVID-19 STUDENT RESPONSE TEAM, EDUCATION COMMITTEE.
Medical Student COVID-19 Curriculum
“A Comparison of Plasmid DNA and mRNA as Vaccine Technologies“,MDPI , Margaret A. Liu, April 19, 2019
nanobodies?
https://www.statnews.com/2020/08/11/scientists-create-potent-anti-coronavirus-nanobody-inspired-by-llamas/
Inspired by llamas’ unique antibodies, scientists create a potent anti-coronavirus molecule — Usha Lee McFarling — August 11, 2020
The lab-made one created by the UCSF team is so stable it can be converted into a dry powder and aerosolized …
“We’d like as soon and as fast as possible to find a partner to make this,” said Peter Walter, a veteran biochemist who permanently resides on many short lists of those expected to win a Nobel Prize and who co-led the project with structural biologist Aashish Manglik.
Their compound, they say, could be cheaply made in enormous quantities using bacteria or yeast, and would require low doses because it is so potent against the virus and can be administered directly to the lungs and or nasal passages.
we can always hope
“The cell is programmed with live genetic material to create the antibodies before being exposed to Covid.”
I wouldn’t call the mRNA “live.” It certainly can’t reproduce itself and doesn’t get copied when it is injected. It is a blueprint for making the spike protein in any cell that receives the mRNA, in this case, the giant syncytial skeletal muscle cells of the bicep.
Joel
Thank you.
I should have said deltoid muscle, not bicep. That’s the site of my injections.
Good Morning Joel:
I have been looking at what I had read trying to ascertain why I wrote what I did. I read something that caused me to think this was correct. Not saying it is. I just like knowing why I did something. This technology is not new and is from the nineties also. Administering it safely to humans appears to be the issue.
@Run,
As with all vaccine trials, there are two issues: safety and efficacy. These were demonstrated for the Moderna mRNA in animal models, else it would not have been advanced to human trials. Phase 1/2 trials demonstrated safety in a small cohort, enough to open the door to phase 3 trials on the scale of 30,000 enrollees (presumably 15K in the vaccine arm). Larger trials have a way of disclosing rare interactions, like the AstraZenica chimp andenovirus vaccine and MS. It I’d had reservations about safety, I wouldn’t have enrolled in the Moderna trial.
Efficacy is trickier since you can’t do a challenge trial for COVID-19 in humans. But built into the large number of participants is the high likelihood that significant numbers in both arms will be infected, and the trial seeks to follow them to determine whether the severity is blunted in the vaccine arm.
Participants agree to the trial terms for two years. Moderna hopes that sufficient safety and efficacy data will emerge by early 2021 to convince the FDA to use the tens of millions of doses the government has already purchased to start general vaccination. I’m sure AstraZenica and others currently trialing their versions hope the same for their vaccines.
Joel:
I agree mRNA did get past 1 and 2 clinical trials. Clinical Trial III is the deal breaker as to whether safety and efficacy meet human requirements. Then too, this is the longest trial. I get the feeling if left to trump, Azar, Moderna Therapeutics this is already decided upon and we will move to using it as a vaccine. I am watching you to see how it evolved for you. They have bumped the trial up to 40,000 too. The FDA is not known for taking things off the market if there are issues with a product of drug. They may black box it the same as they did Essure.
Thank you for the information.
@Run,
Based on my reaction to the booster, I suspect i’m in the vaccine arm. I was able to get an antibody test at our clinic, but only after the test result came back negative did the clinic director admit that they test for the nucleocapsid antibody, not the spike antibody. So I know I haven’t been infected but I don’t know whether I have antibodies to the SARS-CoV-2 spike protein. Since it’s a double-blind study, the docs and nurses don’t know. I’m on the hunt for a commercial antibody test for the spike antibody.
Meanwhile, the fever, muscle/joint aches and headache disappeared by 36 hours after the booster and I’ve been fine ever since. Of course, I’m an anecdote, not data. And even if I am in the vaccine arm, I’m not going to tempt fate; i plan to continue social distancing.
Joel:
When you reported such, the symptoms matched what was reported. Now lets see if it lasts. Growing a tail or a horn does not count. We will be watching.